171 related articles for article (PubMed ID: 31605337)
1. ASO Author Reflections: Value of Cytoreduction in Extensive Ovarian Cancer-Does Surgical Effort Still Matter?
Fotopoulou C
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):786-787. PubMed ID: 31605337
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer.
Marchetti C; Fagotti A; Scambia G; De Felice F
Ann Surg Oncol; 2021 Jun; 28(6):3264-3265. PubMed ID: 33123859
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: Total Parietal Peritonectomy During Interval Cytoreductive Surgery for Advanced Ovarian Cancer-Proof-of-Principle and Analysis of Morbidity.
Bhatt A; Kammar P; Mehta S; Sinukumar S
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):861-862. PubMed ID: 32720047
[No Abstract] [Full Text] [Related]
4. ASO Author Reflections: Surgery and Bevacizumab in Ovarian Cancer.
Petrillo M; Scambia G; Fagotti A
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):886-887. PubMed ID: 30414040
[No Abstract] [Full Text] [Related]
5. ASO Author Reflections: Personalized Surgery in Recurrent Ovarian Cancer Patients.
Estati FL; Baiocchi G; da Costa AABA
Ann Surg Oncol; 2021 Jul; 28(7):3646-3647. PubMed ID: 33211231
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: Rectosigmoid Mesorectal Sparing Resection: A Feasible Technique and a Viable Option in Advanced Ovarian Cancer Surgery.
Rosati A; Vargiu V; Santullo F; Lodoli C; Attalla El Halabieh M; Scambia G; Fagotti A; Costantini B
Ann Surg Oncol; 2021 Oct; 28(11):6723-6724. PubMed ID: 33575871
[No Abstract] [Full Text] [Related]
7. ASO Author Reflections: Redefining Consolidation Cytoreductive Surgery for Ovarian Cancer.
Bhatt A; Alcazer V; Frankinet L; Bakrin N; Glehen O
Ann Surg Oncol; 2023 Jun; 30(6):3300-3301. PubMed ID: 36808321
[No Abstract] [Full Text] [Related]
8. ASO Author Reflections: The PlasmaJet
Nieuwenhuyzen-de Boer GM; van Beekhuizen HJ
Ann Surg Oncol; 2022 Aug; 29(8):4844-4845. PubMed ID: 35482266
[No Abstract] [Full Text] [Related]
9. ASO Author Reflections: Use of Peritoneal Cancer Index (PCI) to Evaluate Carcinomatosis in Ovarian Cancer.
Stålberg K; Jónsdóttir B
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):763-764. PubMed ID: 32468349
[No Abstract] [Full Text] [Related]
10. ASO Author Reflections: Risk Factors for Anastomotic Leakage in Advanced Ovarian Cancer Surgery-What We Know and Future Perspectives.
Vargiu V; Santullo F; Rosati A; Costantini B; Gallotta V; Lodoli C; Pacelli F; Scambia G; Fagotti A
Ann Surg Oncol; 2022 Aug; 29(8):4803-4804. PubMed ID: 35430663
[No Abstract] [Full Text] [Related]
11. ASO Author Reflections: Cisplatin- and Adrenaline-Based Intraperitoneal Chemotherapy Protocol for Ovarian Peritoneal Carcinosis: New Perspectives?
Paquette B
Ann Surg Oncol; 2022 May; 29(5):3335-3336. PubMed ID: 35072865
[No Abstract] [Full Text] [Related]
12. The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer.
Turnbull HL; Akrivos N; Wemyss-Holden S; Maiya B; Duncan TJ; Nieto JJ; Burbos N
Arch Gynecol Obstet; 2017 Mar; 295(3):681-687. PubMed ID: 27995370
[TBL] [Abstract][Full Text] [Related]
13. ASO Author Reflections: Preoperative Staging for Nongynecological Peritoneal Malignancies Mimicking Ovarian Cancer-Making the Omelet without Breaking the Eggs.
Guaglio M; Baratti D
Ann Surg Oncol; 2021 May; 28(5):2909-2910. PubMed ID: 33604826
[No Abstract] [Full Text] [Related]
14. ASO Author Reflections: Peritoneal Metastases from Endometrial Cancer.
Sammartino P; Cornali T
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):882-883. PubMed ID: 30288653
[No Abstract] [Full Text] [Related]
15. ASO Author Reflections: Time to Change: Redefining "Complete Cytoreduction" in Appendiceal Carcinomatosis.
Munoz-Zuluaga C; King MC; Gushchin V; Sardi A
Ann Surg Oncol; 2020 Dec; 27(13):5037-5038. PubMed ID: 32935268
[No Abstract] [Full Text] [Related]
16. ASO Author Reflections: Toward Improved Selection of Patients for Cytoreduction and HIPEC: Identification of Prognostic Factors for Patients with Colorectal Peritoneal Metastases.
Sluiter NR; Tuynman JB
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):840-841. PubMed ID: 30302638
[No Abstract] [Full Text] [Related]
17. Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy.
Baek MH; Lee SW; Park JY; Rhim CC; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2017 Mar; 27(3):420-429. PubMed ID: 28187098
[TBL] [Abstract][Full Text] [Related]
18. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Cascales-Campos PA; Gil J; Feliciangeli E; Gil E; González-Gil A; López V; Ruiz-Pardo J; Nieto A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2015 Mar; 22(3):987-93. PubMed ID: 25212832
[TBL] [Abstract][Full Text] [Related]
19. ASO Author Reflections: Tailoring the Extent of Peritoneal Resection for Peritoneal Metastases According to the Primary Tumor Site.
Bhatt A; Glehen O
Ann Surg Oncol; 2020 May; 27(5):1471-1472. PubMed ID: 32162077
[No Abstract] [Full Text] [Related]
20. ASO Author Reflections: Safety of Abdominal Surgical Cytoreduction Combined with Locoregional Chemohyperthermia.
Piso P
Ann Surg Oncol; 2019 Jan; 26(1):155. PubMed ID: 30478632
[No Abstract] [Full Text] [Related]
[Next] [New Search]
